May 23, 2017
Biocartis launches colorectal cancer test
Biocartis Group, an innovative molecular diagnostics company, has launched of the Idylla NRAS Mutation Test.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
May 23, 2017
SkinBioTherapeutics extents research contract with the University of Manchester
SkinBioTherapeutics, a life science company focused on skin health, has agreed an eight month extension to its research contract with the University of Manchester to June 2018.
May 23, 2017
Oxford BioDynamics signs development agreement with two pharmaceutical companies
Oxford BioDynamics, a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has entered into a development agreement with two pharmaceutical companies, that are collaborating on an anti PD-L1 therapy.
May 23, 2017
AstraZeneca’s Bydureon EXSCEL trial meets type-2 diabetes safety objective
AstraZeneca has reported top-line results from the Phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that compared the effect of once-weekly Bydureon (exenatide extended-release) versus placebo, when added to usual type-2 diabetes care, on the risk of MACE, a composite endpoint of CV death, non-fatal myocardial infarction or non-fatal stroke, in adults with type-2 diabetes (T2D) at a wide range of CV risk.
May 23, 2017
Novartis’ new analyses reinforce the potential of Ultibro & Breezhaler for COPD patients
Novartis’ head-to-head FLAME study suggest that inhaled corticosteroids (ICS) may not be needed in some chronic obstructive pulmonary disease (COPD) patients with high blood eosinophil (a type of white blood cell) counts.
May 23, 2017
Sanofi and Regeneron win FDA approval for its rheumatoid arthritis drug
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s and Regeneron Pharmaceuticals’s Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).
May 23, 2017
Novo Nordisk submits application in the US for label addition for its diabetes drug
Novo Nordisk has submitted a supplemental application to the US Food and Drug Administration (FDA) for including data in the label for Tresiba (insulin degludec) from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba compared to insulin glargine U100 when added to standard of care, in people with type 2 diabetes.
May 22, 2017
AstraZeneca in agreement with Recordati S.p.A for certain commercial rights
AstraZeneca has entered into an agreement with Recordati S.p.A for the commercial rights to Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treatments in Europe.
May 22, 2017
InnovaDerma launches haircare range, enters UK skincare market
InnovaDerma, a UK developer of life sciences, will launch a new haircare product range and its entry into the UK skincare market.
May 22, 2017
Anavex presents new data for certain neuro-diseases tratment
Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, has announced new preclinical data for ANAVEX 2-73 in the neurodevelopmental disorders Angelman syndrome, Fragile X syndrome and Rett syndrome.